Table 1.
Demographic, virological and histological data of patients included in the trial n (%)
| Control group | Group E6 | Group E9 | Group L6 | Group L9 | ||
| Demographics1 and virological response | ||||||
| n = 30 | n = 16 | n = 16 | n = 15 | n = 15 | ||
| Age (yr) | mean ± SD | 48.5 ± 7.4 | 47.4 ± 9.1 | 42.6 ± 7.9 | 47.3 ± 7.5 | 45.3 ± 7.3 |
| Sex | Feminine | 12 (40) | 11 (68.8) | 8 (50.0) | 11 (73.3) | 9 (60) |
| Masculine | 18 (60) | 5 (31.3) | 8 (50.0) | 4 (26.7) | 6 (40) | |
| Body Mass Index | mean ± SD | 26.7 ± 2.8 | 24.8 ± 3.5 | 28.6 ± 4.6 | 25.3 ± 5.0 | 24.9 ± 4.4 |
| Race | White | 16 (53.3) | 12 (75.0) | 11 (68.8) | 10 (66.7) | 8 (53.3) |
| Black | 4 (13.3) | 3 (18.8) | 3 (18.8) | 4 (26.7) | 3 (20.0) | |
| Mixed | 10 (33.3) | 1 (6.3) | 2 (12.5) | 1 (6.7) | 4 (26.7) | |
| Response to treatment2 | cEVR | 18 (60.0) | 10 (62.5) | 9 (56.3) | 7 (46.7) | 4 (26.7) |
| SVR | 14 (46.7) | 8 (50) | 8 (50) | 7 (46.7) | 2 (13.3) | |
| Histology3 | ||||||
| Week 0 | n | 30 | 16 | 16 | 15 | 15 |
| Necroinflammation | mean ± SD | 6.7 ± 3.6 | 6.4 ± 3.2 | 6.1 ± 3.3 | 5.1 ± 3.4 | 7.0 ± 4.1 |
| Fibrosis | 1.6 ± 1.4 | 1.9 ± 1.3 | 1.4 ± 1.4 | 1.6 ± 1.3 | 2.3 ± 1.8 | |
| Week 72 | n | 19 | 13 | 14 | 9 | 8 |
| Necroinflammation | mean ± SD | 3.3 ± 2.5 | 3.8 ± 2.2 | 3.2 ± 2.8 | 4.9 ± 3.0 | 5.6 ± 3.2 |
| Fibrosis | 1.3 ± 1.5 | 2.1 ± 1.3 | 1.1 ± 1.3 | 2.1 ± 1.6 | 2.5 ± 1.6 | |
1
Corresponding to baseline;
2
By intention to treat;
3
According to Ishak score[17]. cEVR: Complete early viral responders; SVR: Sustained viral responders.